long intergenic non-protein coding RNA 934Genealiases: []
Q-omics provides the consensus-scored LINC00934 profile across patient tissues and cancer cell-line models. LINC00934 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in THYM. Among the 18 cancer types available for tumor–normal comparison, LINC00934 is differentially expressed in 4, with the highest sampling consensus in BLCA. Additionally, LINC00934 RNA expression shows 7,882 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight THYM, BLCA, and UVM as cancer lineages where LINC00934 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00934 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00934 survival associations across molecular data types. LINC00934 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00934 RNA expression–survival associations across cancer types. High LINC00934 expression shows unfavorable associations in THYM, TGCT, BRCA, LUAD and DLBC, but favorable associations in MESO. The THYM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THYM as the clearest survival context for LINC00934 RNA expression.
This table summarizes LINC00934 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00934. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00934 shows lower tumor expression in BLCA, THCA, KIRP and LUSC. The BLCA box plot shows higher LINC00934 RNA expression in normal versus tumor tissue (log2 FC = −0.019, t-test p = .006).
This table shows molecular features associated with LINC00934 in patient tissues and cancer cell lines. In patient samples, LINC00934 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
